PhagePro

PhagePro, founded as an early-stage biotechnology company, is dedicated to developing bacteriophage-based therapeutics aimed at addressing the needs of the world's most vulnerable communities. Their core mission is to leverage the power of phages to combat antibiotic resistance and promote health equity globally. PhagePro's innovative products focus on providing effective treatments for bacterial infections that are increasingly resistant to traditional antibiotics, thereby contributing to global health solutions.

Notable figures associated with PhagePro include experts in microbiology and biotechnology who have a shared vision of combating antibiotic resistance. The company has garnered attention for its pioneering approach and has attracted investment from stakeholders committed to advancing public health. PhagePro's key achievements include the development of promising phage therapies that have shown potential in preclinical trials, positioning them as a significant player in the fight against antibiotic-resistant infections. Their impact lies in their commitment to making advanced medical treatments accessible to underserved populations worldwide.